Artes Medical forms non-aesthetic microsphere technology arm:
This article was originally published in Clinica
Executive Summary
San Diego, California-based aesthetic injectable products company Artes Medical has formed a new subsidiary to focus on new applications of its microsphere tissue bulking technology. Spheris Medical will develop and commercialise the technology for therapeutics uses, such as in soft tissue augmentation products. The microspheres have been assessed in preclinical studies as a bulking agent for the oesophageal sphincter to treat gastro-oesophageal reflux disease (GERD) and for the urinary sphincter to treat stress urinary incontinence. Other potential uses of the technology include spinal disc bulking and repair; sleep apnoea treatment (by bulking the soft palate and respiratory tissue); and foecal incontinence treatment.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.